Citation Impact
63 standout
Citing Papers
The hallmarks of cancer immune evasion
2024 Standout
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
2024 Standout
Works of Murray Brunt being referenced
AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.
2018
Author Peers
| Author | PRM | Oncology | Cancer Research | Molecular Biology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Murray Brunt | 34 | 46 | 25 | 25 | 7 | 65 | |
| Leroy D. Mell | 3 | 1 | 1 | 127 | 16 | 765 | |
| Seyed Majid Zabihzadeh | 1 | 9 | 23 | 400 | |||
| Amir Kiumarsi | 4 | 3 | 41 | 14 | 648 | ||
| Maria Luisa Focarelli | 7 | 27 | 28 | 499 | 7 | 548 | |
| Thomas Way | 1 | 9 | 33 |
All Works
Loading papers...